Understanding Major Depressive Disorder and Its Physiological Links
Major Depressive Disorder (MDD) represents a significant global health challenge, affecting millions worldwide across all age groups, with a notable increase in prevalence among young people, according to the Pan American Health Organization (PAHO) and the World Health Organization (WHO). Symptoms often include depressed mood, low self-esteem, fatigue, anxiety, and disturbances in sleep and appetite. Emerging evidence indicates that the pathophysiology of MDD involves a complex interaction between chronic stress, dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, immune activation, and neuroinflammation.
The HPA axis plays a crucial role in the body’s stress response, modulating cortisol release. Dysfunction in this system is associated with various conditions, including MDD. Studies suggest that increased HPA axis activity, often observed in chronic stress, contributes to neuroinflammation and mood changes in MDD. Normally, cortisol helps to reduce inflammation, but persistent stress can lead to HPA axis hyperactivity, excessive glucocorticoid release, and a dysregulation of its negative feedback loop. This can result in glucocorticoid resistance and the release of pro-inflammatory cytokines by immune cells, as detailed in a review published in Frontiers in Pharmacology.
Neuroinflammation, an abnormal immune response within the brain, involves various cell types such as microglia and astrocytes. This inflammation and subsequent alterations in brain regions vital for emotional regulation are associated with MDD pathophysiology. Markers of neuroinflammatory processes linked with depression include interleukins, TNF-α, interferons, and translocator protein (TSPO).
The HPA Axis, Inflammation, and Immunophilins
Recent literature highlights the importance of proteins that modulate cortisol sensitivity, specifically FK506-binding protein 51 (FKBP51) and FK506-binding protein 52 (FKBP52). These proteins directly influence the HPA axis and glucocorticoid receptor function. Research indicates that FKBP51 levels may be elevated in situations of chronic stress and in individuals with depression. When FKBP51 is elevated, the glucocorticoid receptor responds less efficiently, potentially affecting the HPA axis’s negative feedback and maintaining the system in prolonged activation.
Conversely, FKBP52 appears to facilitate the proper function of the glucocorticoid receptor. An imbalance between FKBP51 and FKBP52 can lead to glucocorticoid resistance. In this state, even with circulating cortisol, the immune system may continue to produce inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α). These cytokines can affect brain regions involved in mood, motivation, and energy, potentially contributing to symptoms like fatigue and persistent sadness.
The regulation of the HPA axis also exhibits sexual dimorphism, with distinct responses observed between males and females. Some experimental models suggest that females may show impaired regulation of glucocorticoid receptor nuclear translocation and disorganized FKBP51 localization, potentially contributing to a higher prevalence and vulnerability of women to MDD.
Potential Role of Medical Cannabis in Modulating These Pathways
Against this complex background, growing attention has been directed toward medical cannabis and depression, specifically *Cannabis sativa* and its bioactive constituents, as potential agents for investigation. The plant, which has been used for thousands of years, contains numerous substances, including cannabinoids and terpenes, known for their physiological and pharmacological effects.
- Phytocannabinoids: Compounds like tetrahydrocannabinol (THC) and cannabidiol (CBD) are extensively studied. THC is noted for its antiemetic and anti-inflammatory activities, as well as its potential to reduce neuropathic and chronic pain.
- Cannabidiol (CBD): CBD exhibits a broad spectrum of biological activities, including antioxidant and anti-inflammatory actions, which may be relevant for conditions associated with redox imbalance and inflammation.
Preclinical and clinical evidence suggests that cannabinoids may modulate the endocannabinoid system, attenuate HPA axis hyperactivity, reduce neuroinflammation, and influence pathways related to monoaminergic neurotransmission and neuroplasticity. This review synthesises current literature on the mechanistic links among the HPA axis, inflammation, and MDD, highlighting the emerging role of *Cannabis sativa*-derived compounds in targeting these interconnected pathways. While these findings are promising, further studies are needed to fully understand the properties and safety of medical cannabis for these applications.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
